Activation of the Farnesoid X-receptor in breast cancer cell lines results in cytotoxicity but not increased migration potential
Breast cancer is the commonest form of cancer in women, but successful treatment is confounded by the heterogeneous nature of breast tumours: Effective treatments exist for hormone-sensitive tumours, but triple-negative breast cancer results in poor survival. An area of increasing interest is metabolic reprogramming, whereby drug-induced alterations in the metabolic landscape of a tumour slow tumour growth and/or increase sensitivity to existing therapeutics. Nuclear receptors are transcription factors central to the expression of metabolic and transport proteins, and thus represent potential targets for metabolic reprogramming. We show that activation of the nuclear receptor FXR, either by its endogenous ligand CDCA or the synthetic GW4064, leads to cell death in four breast cancer cell lines with distinct phenotypes: MCF-10A (normal), MCF-7 (receptor positive), MDA-MB-231 and MDA-MB-468 (triple negative). Furthermore, we show that the mechanism of cell death is predominantly through the intrinsic apoptotic pathway. Finally, we demonstrate that FXR agonists do not stimulate migration in breast cancer cell lines, an important potential adverse effect. Together, our data support the continued examination of FXR agonists as a novel class of therapeutics for the treatment of breast cancer. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
Apoptosis Autophagy Nuclear receptor Triple negative breast cancer Bile acids ORPHAN NUCLEAR RECEPTOR BILE-ACIDS GENE-EXPRESSION DOWN-REGULATION AUTOPHAGY DEATH IDENTIFICATION APOPTOSIS THERAPY DRUGS
Clinical PD Biomarker Group
License start date
CANCER LETTERS, 2016, 370 (2), pp. 250 - 259